NASDAQ: ALMS
Alumis Inc. Common Stock
Healthcare · Biotechnology
Per-share valuation inputs need verification
Event dated Dec 31, 2025Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$3.06B
52w High
$30.60
52w Low
$2.76
P/E
-10.70
Volume
841.72K
Outstanding Shares
123.14M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 457.4% over the last year. Free cash flow declined 44.14% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -1,837.44%. A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
8
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 13, 2026
Q2 FY26 · EPS est -$0.79 · Revenue est $2.49M
View